Immediate Impact
8 from Science/Nature 57 standout
Citing Papers
Natural killer cell therapies
2024 StandoutNature
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Works of David Hoffman being referenced
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
2022
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| David Hoffman | 1322 | 173 | 331 | 425 | 420 | 61 | 2.0k | |
| Kap Bum Huh | 1047 | 130 | 449 | 442 | 298 | 114 | 2.3k | |
| Kazunari Matsumoto | 660 | 108 | 270 | 216 | 445 | 50 | 1.8k | |
| W. H. L. Hackeng | 517 | 193 | 287 | 203 | 281 | 72 | 1.9k | |
| Jehangir Mistry | 834 | 251 | 246 | 228 | 681 | 45 | 1.6k | |
| Anthony J. Proudler | 931 | 63 | 486 | 321 | 185 | 33 | 1.8k | |
| Pascale H. Lane | 410 | 69 | 309 | 199 | 361 | 52 | 1.8k | |
| Adam M. Smiles | 817 | 67 | 279 | 286 | 706 | 33 | 3.1k | |
| Manjula K. Gupta | 1054 | 276 | 130 | 286 | 507 | 91 | 2.5k | |
| Maki Urushihara | 695 | 89 | 1001 | 183 | 582 | 79 | 2.5k | |
| Robert U. Simpson | 284 | 164 | 345 | 362 | 636 | 61 | 3.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...